Popular stocks:
Suncor Energy
Boeing
NVIDIA
Tilray
Norwegian Cruise Line
Microsoft
Eli Lilly and Comp.
Micron
New Oriental Education & Technology Group
Shares of other companies:
September 8, 2024 S&P 500 In Freefall: Is This The End Of The Bull Market?
September 6, 2024 Jobs Report Spotlight As Fed Weighs Rate Cut Decision
August 26, 2024 NVDA Earnings Report Insights
August 22, 2024 Massive U.S. Job Growth Revision Shakes Economy And Markets
Nvidia: The Blackwell Delay And Its Consequences
September 6, 2024
Nvidia Q2 Offers Several Clues To Sustainable Growth Ahead
September 6, 2024
The Power Of Expectations: Nvidia’s Earnings And The Market Reaction
September 6, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
CRSP Stock News and Mentions of CRISPR Therapeutics AG Stocktwits
Updated: September 8, 2024 (00:06)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where CRISPR Therapeutics Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of CRISPR Therapeutics AG (CRSP).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the CRISPR Therapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of CRISPR Therapeutics AG (CRSP)
September 4, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is CRISPR Therapeutics ( CRSP ) Down 7.7% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
August 8, 2024 (13:29) / "Benzinga" (by Avi Kapoor)
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom - ONEOK ( NYSE:OKE )
On CNBC's "Mad Money Lightning Round," Jim Cramer said Oneok OKE is "terrific" and recommended buying more of the stock. On Aug. 5, ONEOK reported better-than-expected second-quarter GAAP EPS results, posting quarterly earnings of $1.33 per share which beat the analyst consensus estimate of $1.21 ...
In Article Trend: Neutral
August 6, 2024 (14:37) / "Zacks Commentary" (by Zacks Equity Research)
CRISPR Therapeutics ( CRSP ) Q2 Loss Wider Than Expected
CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.
In Article Trend: Neutral
August 5, 2024 (21:25) / "Zacks Commentary" (by Zacks Equity Research)
CRISPR Therapeutics AG ( CRSP ) Reports Q2 Loss, Misses Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.76% and 93.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
August 1, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Gilead Sciences ( GILD ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
July 30, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Investors Heavily Search CRISPR Therapeutics AG ( CRSP ) : Here is What You Need to Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
July 30, 2024 (12:40) / "Zacks Commentary" (by Zacks Equity Research)
Day One Biopharmaceuticals, Inc. ( DAWN ) Reports Q2 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 92.54% and 810.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
July 29, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Analysts Estimate CRISPR Therapeutics AG ( CRSP ) to Report a Decline in Earnings: What to Look Out for
CRISPR Therapeutics (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
July 26, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
CRISPR Therapeutics AG ( CRSP ) Ascends But Remains Behind Market: Some Facts to Note
CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $57.92, signifying a +0.61% move from its prior day's close.
In Article Trend: Somewhat-Bullish
July 23, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
CRISPR Therapeutics AG ( CRSP ) Increases Despite Market Slip: Here's What You Need to Know
CRISPR Therapeutics AG (CRSP) closed at $57.19 in the latest trading session, marking a +1.69% move from the prior day.
In Article Trend: Neutral
July 23, 2024 (13:48) / "Zacks Commentary" (by Zacks Equity Research)
Is a Beat in the Cards for CRISPR ( CRSP ) in Q2 Earnings?
On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.
In Article Trend: Somewhat-Bullish
July 22, 2024 (14:31) / "Zacks Commentary" (by Zacks Equity Research)
What's in Store for ADMA Biologics ( ADMA ) in Q2 Earnings?
On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
In Article Trend: Somewhat-Bullish
July 17, 2024 (10:08) / "Zacks Commentary" (by Zacks Equity Research)
CRISPR Therapeutics ( CRSP ) Moves 9.2% Higher: Will This Strength Last?
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
In Article Trend: Somewhat-Bullish
July 11, 2024 (11:15) / "Benzinga" (by Benzinga Neuro)
Cathie Wood Touts Palantir, Coinbase And Roku As ARK's Flagship Fund Shifts Focus From Mag 6 Amid 'Whiff' Of Lower Interest Rates - ARK Genomic Revolution ETF ( BATS:ARKG ) , ARK Innovation ETF ( ARCA:ARKK )
In a recent letter to investors, Cathie Wood, the CEO of ARK Invest, highlighted the potential of the company's flagship fund, ARK Innovation ETF ARKK, despite its recent underperformance.
In Article Trend: Somewhat-Bullish
July 10, 2024 (22:00) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why CRISPR Therapeutics AG ( CRSP ) Gained But Lagged the Market Today
CRISPR Therapeutics AG (CRSP) closed at $55.56 in the latest trading session, marking a +0.96% move from the prior day.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website